Replies to post #58214 on Bagman's charts, watchlists, scans and etc.

[gb55]

great idea

[I- B- N]

CXM ~~~On March 12, 2010, we offered and sold 2,266,998 units pursuant to the final prospectus supplement dated March 9, 2010, and our previously filed registration statement on Form S-3 (Registration No. 333-147947), which was declared effective by the Securities and Exchange Commission on December 19, 2007. Each unit in the offering consisted of ten shares of our common stock, par value $0.0001 per share, and a warrant to purchase five shares of our common stock. Each warrant will entitle its holder to purchase five shares of our common stock and will be exercisable at any time on or after six months from the date of issuance for a period of five years from that date. Units will not be issued or certificated. The units will separate immediately and the common stock and warrants will be issued separately and the common stock will trade separately. The warrants will be issued in “book entry” form pursuant to the terms of a warrant agreement between us and Computershare Trust Company, N.A., who will act as warrant agent. The selling price for the units was $5.00 per unit and the exercise price for the warrants is $0.64.

[Den]

where do u go to find them ?

[**D*A**]

CXM

[**D*A**]

DDSS (1.50)

[**D*A**]

SUF (.39)

[gb55]

hi bro...i don't know if this is helpful or not....wish i had time to dig into this with ya


Secondary or Follow-On Offerings:
Bank of Commerce Holdings (BOCH)--6 million shares expected to price Tuesday via Howe Barnes Hoefer & Arnett. Consol Energy (CNX)--38.5 million shares expected to price Thursday via Bank of America Merrill Lynch, PNC Bank, Scotia Capital and Stifel Nicolaus. Flagstar Bancorp Inc. (FBC)--$250 million in shares expected to price Wednesday via Sandler O'Neill. Gafisa SA (GFA)--37 million American depositary shares expected to price Tuesday via UBS. Linn Energy LLC (LINE)--12 million shares expected to price Tuesday via Barclays, Citigroup, RBC Capital, UBS Securities and Wells Fargo. Massey Energy Co. (MEE)--8.5 million shares expected to price Tuesday via UBS Securities. Orrstown Financial Services Inc. (ORRF)--$40 million in shares expected to price Tuesday via Sandler O'Neill. Somaxon Pharmacueticals Inc. (SOMX)--4 million shares expected to price Thursday via Jefferies. ViaSat Inc. (VSAT)--5.5 million shares expected to price Thursday via Morgan Stanley, Bank of America Merrill Lynch and Credit Suisse.

[**D*A**]

YMI (1.16)

[**D*A**]

DSCO (.52)

[gb55]

12/17/09
Opexa Therapeutics Closes $5.1 Mln Registered Direct Offering - Quick Facts

(RTTNews) - Thursday, Opexa Therapeutics Inc. (OPXA) completed its registered direct offering with several institutional investors to sell 2.55 million units. Each unit consist of one share of Opexa common stock, a five-year Series A warrant to purchase 0.35 of an additional share of Opexa common stock, and a one-year Series B warrant to purchase 0.15 of an additional share of Opexa common stock.

The price of the securities sold was $2.00 per unit, for an aggregate purchase price of $5.1 million. Following to a securities purchase agreement between Opexa and the investors in this offering, the warrants are exercisable at $2.55 per share and are first exercisable on June 15, 2010. The Series A Warrants expire on June 15, 2015 and the Series B Warrants expire on June 15, 2011.

[**D*A**]

FBC - thanks for bringing this to my attention NoviceTrader. I'm not in at the moment, but rooting hard for you.

[gb55]

do you want to include private placements?

U.S. Geothermal Inc. (TSX:GTH - News)(AMEX:HTM - News) (the "Company") announced today closing of a private placement financing pursuant to which the Company has issued 8,209,519 shares of Common Stock at a price of $1.05 per share for gross proceeds of $8.6 million (the "Private Placement"). Each Investor was also issued a common share purchase warrant (a "Warrant") exercisable for 50% of the number of shares of Common Stock purchased by the investor. Each Warrant is exercisable at $1.25 per share for a period of five years beginning September 16, 2010.

[**D*A**]

WZE closed an offering at .25 on April 1st.

[**D*A**]

TIV - public offering

[Den]

DVAX $1.39 ~>Dynavax Raises $44 Million Through Public Offering of Common Stock and Warrants
Transaction Expected to Close April 16, 2010


DVAX 1.39 0.00


BERKELEY, CA--(Marketwire - 04/13/10) - Dynavax Technologies Corporation (NASDAQ:DVAX - News) today announced the pricing of an underwritten offering resulting in gross proceeds of $44 million, before deducting estimated offering expenses. 30,293,000 units are being sold at a per unit price of $1.4525. Each unit consists of one share of common stock and one warrant to purchase 0.5 of a share of common stock. Each warrant has an exercise price of $1.50 per share and is exercisable for a period of five years from the date of issuance.

http://finance.yahoo.com/news/Dynavax-Raises-44-Million-iw-4098961697.html?x=0&.v=1

[**D*A**]

COIN - I'm sorry for bringing this old wound up guys. It does fit the offering play well. To be honest, COIN was the stock that got me started on the offerings. I traded it because of the chart and was already in when the offering closed a few years ago. It ran shortly after and got my attention. I started watching them since and really like the plays.

[**D*A**]

DRYS (6.16)

[**D*A**]

HDY (1.23) - thanks I-B-N, I'm responding to this post so I can keep easier track of the offering plays. I've been selling the runners and putting them into the laggers. Its been working well lately.

[**D*A**]

NLTX (.69)

http://www.prnewswire.com/news-releases/nile-therapeutics-announces-closing-of-public-offering-92225099.html

[novicetrader]

CODI..does this one qualify?This is a dividend paying stock too,I liked it & had intended getting in before divy date but somehow chickened out.Still on my watchlist though.

[novicetrader]

CNXT..this seems to have had an offering in early march at $4.00 per share.I bought some today @3.20 on the big drop on earnings news which wasn't even bad(believe they exceeded guidance).Funky market,anything can happen,but I'm hoping for a nice enough pop on this.
http://biz.yahoo.com/ap/100305/us_conexant_offering.html?.v=2

[Den]

Nile Therapeutics Announces Pricing of Public Offering

Buzz up! 0 Print..Companies:Nile Therapeutics, Inc.Related Quotes
Symbol Price Change
NLTX 0.68 +0.01


{"s" : "nltx","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: Nile Therapeutics, Inc. On Thursday April 22, 2010, 8:00 am EDT
SAN MATEO, Calif., April 22 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq:NLTX - News), a company focused on the development of novel therapeutics for heart failure patients, announced the pricing of its previously announced underwritten public offering of 6,500,000 units of its securities at a public offering price of $0.70 per unit. Each unit consists of one share of Nile common stock and 0.30 warrants to purchase common stock. Each warrant has a term of five years and represents the right to purchase one share of common stock at an exercise price of $0.94 per share. No fractional warrants will be issued. The units will immediately separate and the common stock and warrants will be issued separately. The warrants have been approved for trading on the Nasdaq Capital Market under the symbol "NLTXW" and are expected to begin trading on or promptly following April 22, 2010. The offering is expected to close on or about April 27, 2010, subject to customary closing conditions.

Maxim Group LLC is acting as the sole book-running manager for this offering, with Ladenburg Thalmann & Co. Ltd. as co-manager. Nile has granted the underwriters an option for a period of 45 days to purchase up to an additional 975,000 units to cover over-allotments, if any.

The net proceeds from the sale of the units, after deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $4.0 million. The Company plans to use the net proceeds from this offering to fund the previously announced expansion of its ongoing Phase II clinical trial of CD-NP in acute heart failure patients, and for general corporate purposes and working capital.

The offering described above is being made pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission on March 12, 2010. A preliminary prospectus supplement relating to the offering was filed with the SEC on April 12, 2010, and is available on the SEC's website at http://www.sec.gov. A final prospectus supplement relating to the offering will also be filed with the SEC. When available, copies of the final prospectus supplement may also be obtained from Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174, or by telephone at 212-895-3685 begin_of_the_skype_highlighting 212-895-3685 end_of_the_skype_highlighting.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, units, shares of common stock or warrants. Furthermore, Nile will not sell any of the units and has been advised by Maxim Group that the underwriters and their affiliates will not sell any of the units in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of the securities under the securities laws of any such state or jurisdiction.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the timing, size and completion of the proposed offering and the expected net proceeds therefrom, the timing, progress and anticipated results of Nile's ongoing clinical trial of CD-NP, and the anticipated benefits of CD-NP, are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's ability to complete the proposed offering, market conditions, the satisfaction of closing conditions, as well as risks and uncertainties associated with Nile's business and finances in general, and the other risks described under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission on March 3, 2010. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
NLTX - Daily Candlesticks

[gb55]

do bb's deserve a look?

04/08/10)Global Health Ventures Inc. (OTC.BB:GHLV - News) (the "Company") is pleased to announce that, it has completed a non-brokered private placement using Regulations S ("Reg S") Exemption from the registration statement. The Company issued 625,000 units at a price of $0.80 per unit for gross proceeds of $500,000. Each unit consists of one common share and one share purchase warrant. Each share purchase warrant is exercisable into one additional common share of the Company at a price of $1.20 per share until April 08, 2015.

[gb55]

April 6, 2010
the terms of the definitive agreements, the investors purchased 3,846,154 shares of Tri-Valley's common stock at $1.30 per share, for a total of $5.0 million in gross proceeds, and received warrants to purchase up to 2,307,692 shares (the "Warrants") in the aggregate. The Warrants include Series A Warrants to purchase up to 1,153,846 shares of common stock at $1.50 per share for five years and Series B Warrants to purchase up to 1,153,846 shares of common stock at $1.95 per share for seven years. Subject to certain limitations, the Company may also be obligated to issue to the investors a limited number of additional shares pursuant to certain purchase price share adjustments on July 2, 2010 and December 1, 2010 that may occur dependent upon the then current price of the Company’s common stock in relation to the original issue price

[novicetrader]

PMI(now $4.69,offering price in end-April was $6.15)..Didn't remember to post this on the offering thread.I think it should gradually inch up closer to the offering price range.Any thoughts?

The PMI Group, Inc. Announces Pricing of Common Stock and Convertible Senior Notes Offerings
WALNUT CREEK, Calif., April 27 /PRNewswire-FirstCall/ -- The PMI Group, Inc. (NYSE:PMI - News) today announced that it has agreed to sell in concurrent underwritten public offerings an aggregate of 77,765,000 shares of its common stock at a price to the public of $6.15 per share and $261 million aggregate principal amount of its 4.50% Convertible Senior Notes due 2020.

[lexi2004]

From: lexi2004 6/11/2010 10:25:15 AM
of 205255

AGEN moving up. @ .9089 Volume 257K

Antigenics Inc., a biotechnology company, develops and commercializes technologies to treat cancers and infectious diseases primarily based on immunological approaches. The company?s product includes Oncophage, a patient-specific therapeutic cancer vaccine tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma, as well as in Phase II clinical trial for the treatment of glioma. Its product candidate portfolio also includes QS-21 Stimulon adjuvant, which is in Phase III third-party clinical trials for various diseases, including hepatitis, human immunodeficiency virus, influenza, cancer, Alzheimer?s disease, malaria, and tuberculosis; AG-707, a therapeutic vaccine program tested in a Phase I clinical trial for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic tested in a Phase I clinical trial for the treatment of solid malignancies and B-cell lymphomas. The company was formerly known as Antigenics L.L.C. and changed its name to Antigenics Inc. in February 2000. Antigenics Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

=====================
Antigenics Sees Encouraging Results; Good Long Term Pick
4 comments | by: VFC's Stock House May 26, 2010 | about: AGEN
It's been a long road for Antigenics (AGEN) since announcing that Russia had approved Oncophage for the treatment of kidney cancer in April of 2008, based on a subset of patients from a Phase III trial. Although the trial results were not thought to be encouraging enough to be brought before the US FDA, Antigenics applied for approval in Europe based on the same subset data that convinced Russia to approve, but were denied this time, sending the AGEN stock back to the sub-$1 level after having had an impressive run during 2009.

After trading at those levels for most of 2010, AGEN had a bit of a bounce back of late, hitting as high as just over $1.70, although no significant news had been released to spur such a spike in price.

Last week, however, the company announced encouraging results from a Phase I/II trial at the International Conference on Brain Tumor Research and Therapy, offering new life to Oncophage and drawing new attention to the stock. Any move towards approval is still a long way off, but Oncophage - awarded as the World Vaccine Congress "best therapeutic vaccine" in April, 2009 - could still have an impressive future, based on current developments and past events.

Oncophage is currently in various stages of development to treat a variety of cancer conditions and QS-21, Antigenics' vaccine adjuvant is being tested in numerous investigational vaccines and the company will receive some future royalty payments if any of those vaccines makes it to market.

It's also possible that Oncophage for kidney cancer is not a complete dud, as I believe that big pharma with big pockets could revive that indication in the event of either a buyout or partnership - a possibility that grows more probable with each passing day, in my opinion. I'm a fan of the future of cancer immunotherapy treatments, and it's still quite possible that Antigenics will play a large role in that future.

That said, AGEN is still a speculative stock and the current volatility should be used to flip a few trading shares, in my opinion, to protect against any future unexpected negative results.

I still like AGEN as a nice long term pick; any short to mid term stock gains would be the result of buyout / partnership talk or a revival of the kidney cancer treatment indication.

All just my opinion, each investor should do his or her own DD.

Disclosure: Long AGEN.

[gb55]

yowza...most of the offering plays have got beat to a pulp!....many are deeply discounted from the offering price...

[Den]

saw DSCO ? public offering

Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that it has priced an underwritten public offering of 35,714,286 units at a price to the public of $0.28 per unit for gross proceeds of $10.0 million. Each unit consists of (i) one share of common stock, (ii) a five-year warrant to purchase 0.50 of a share of common stock and (iii) a short-term warrant to purchase 0.50 of a share of common stock. The shares of common stock and warrants are immediately separable and will be issued separately such that no units will be issued. The five-year warrants are exercisable immediately upon issuance, have a five-year term and an exercise price of $0.40 per share. The short-term warrants are exercisable immediately upon issuance, have a nine-month term and an exercise price of $0.28 per share. Net proceeds, after estimated underwriting discount and other estimated fees and expenses payable by Discovery Labs, and assuming the warrants are not exercised, will be approximately $9.1 million. The offering is expected to close on or about June 22, 2010, subject to satisfaction of customary closing conditions.

DSCO - Daily Candlesticks